Asunto(s)
Adaptación Fisiológica/fisiología , Prueba de Esfuerzo/métodos , Ejercicio Físico/fisiología , Corazón Auxiliar/tendencias , Descanso/fisiología , Función Ventricular Derecha/fisiología , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Proyectos Piloto , Estudios Prospectivos , Factores de TiempoRESUMEN
AIMS: Exercise stress testing (EST) is recommended by guidelines to risk-stratify patients with asymptomatic valvular aortic stenosis (AS), though the role of quantitative exercise-Doppler echocardiography has rarely been studied. This prospective study sought to correlate standard EST results with the haemodynamic measurements made during exercise by Doppler echocardiography. METHODS AND RESULTS: We performed rest and semi-supine exercise Doppler echocardiography in 44 consecutive patients (mean age=68+/-12 years) with aortic valve areasAsunto(s)
Estenosis de la Válvula Aórtica/diagnóstico por imagen
, Ecocardiografía Doppler/métodos
, Ecocardiografía de Estrés/métodos
, Hemodinámica/fisiología
, Anciano
, Estenosis de la Válvula Aórtica/diagnóstico
, Gasto Cardíaco
, Ecocardiografía/métodos
, Femenino
, Frecuencia Cardíaca
, Humanos
, Masculino
, Persona de Mediana Edad
, Probabilidad
, Estudios Prospectivos
, Valores de Referencia
, Análisis de Regresión
, Reproducibilidad de los Resultados
, Medición de Riesgo
, Sensibilidad y Especificidad
, Índice de Severidad de la Enfermedad
, Volumen Sistólico
RESUMEN
BACKGROUND: The rate of pacemaker implantation is rising. Given that the life expectancy of the population is projected to increase, a large number of elderly patients are likely to be implanted in the future. As pacemaker batteries can last for 8-10years, an increasing number of pacemaker recipients will require replacement of their devices when they become nonagenarians. AIMS: To analyse the short- and long-term outcomes after device replacement in nonagenarians. METHODS: Patients aged≥90years referred to a tertiary centre for pacemaker replacement from January 2004 to July 2014 were included retrospectively. Clinical follow-up data were obtained from clinical visits or telephone interviews with patients or their families. The primary clinical endpoint was total mortality. Secondary endpoints included early and delayed procedure-related complications and predictive risk factors for total mortality. RESULTS: Sixty-two patients were included (mean age 93.3±2.9years at time of pacemaker replacement). Mean procedure duration was 35.7±17.2minutes. Mean hospital stay was 2.2±1.1days. One patient died from a perioperative complication. Thirty-seven patients (59.7%) died during a median follow-up of 22.1months (interquartile range, 11.8-39.8months). Survival rates were 84.2% (95% confidence interval [CI] 71.8-91.5%) at 1year, 66.9% (95% CI 51.8-78.2%) at 2years and 22.7% (95% CI 10.6-37.7%) at 5years. Atrial fibrillation (hazard ratio 2.47, 95% CI 1.1-5.6) and non-physiological pacing (i.e. VVI pacing in patients in sinus rhythm) (hazard ratio 2.20, 95% CI 1.0-4.9) were predictors of mortality. CONCLUSIONS: Pacemaker replacement in nonagenarians is a safe and straightforward procedure. These data suggest that procedures can be performed securely in this old and frail population, with patients living for a median of 30months afterwards.
Asunto(s)
Arritmias Cardíacas/terapia , Marcapaso Artificial , Factores de Edad , Anciano de 80 o más Años , Anticoagulantes/uso terapéutico , Bloqueo Atrioventricular/terapia , Causas de Muerte , Comorbilidad , Remoción de Dispositivos , Falla de Equipo , Femenino , Estudios de Seguimiento , Humanos , Estimación de Kaplan-Meier , Masculino , Mortalidad , Marcapaso Artificial/efectos adversos , Inhibidores de Agregación Plaquetaria/uso terapéutico , Estudios Retrospectivos , Factores de RiesgoRESUMEN
OBJECTIVES: The aim of this multicenter study was to evaluate the prognostic impact of a therapeutic strategy using plasma brain natriuretic peptide (BNP) levels. BACKGROUND: The prognosis of chronic heart failure (CHF) remains poor, even among patients treated in specialized departments. METHODS: A total of 220 New York Heart Association functional class II to III patients considered optimally treated with angiotensin-converting enzyme inhibitors (ACEIs), beta-blockers, and diuretics by CHF specialists were randomized to medical treatment according to either current guidelines (clinical group) or a goal of decreasing BNP plasma levels <100 pg/ml (BNP group). Outpatient visits were scheduled every month for 3 months, then every 3 months. The primary combined end point was CHF-related death or hospital stay for CHF. RESULTS: Both groups were similar for baseline clinical and biological characteristics. Left ventricular ejection fraction was slightly lower in the BNP group than in the clinical group (29.9 +/- 7.7% vs. 31.8 +/- 8.4%, p = 0.05). At the end of the first 3 months, all types of drugs were changed more frequently in the BNP group. Mean dosages of ACEIs and beta-blockers were significantly higher in the BNP group (p < 0.05), whereas the mean increase in furosemide dosage was similar in both groups. During follow-up (median 15 months), significantly fewer patients reached the combined end point in the BNP group (24% vs. 52%, p < 0.001). CONCLUSIONS: In optimally treated CHF patients, a BNP-guided strategy reduced the risk of CHF-related death or hospital stay for CHF. The result was mainly obtained through an increase in ACEI and beta-blocker dosages.